Lenvatinib in Advanced HCC: Considerations for Monotherapy and Combination Regimens
Panelists discuss how ongoing trials in first-line advanced hepatocellular carcinoma (HCC) may reshape treatment paradigms, influencing tyrosine kinase inhibitor (TKI) and immune checkpoint inhibitor (ICI) use. Patient selection depends on clinical (liver function, ECOG status) and biological (PD-L1, VEGF expression) factors. Lenvatinib remains a key TKI, balancing efficacy and safety. As emerging regimens (CARES-310, CheckMate-9DW) gain traction, lenvatinib’s role evolves, with experts assessing its place in monotherapy and combinations.
Video content above is prompted by the following:
- Discuss the potential implications of ongoing trials in the first-line space.
- What clinical and biological factors help determine whether a patient would benefit more from a TKI alone vs a combination with an ICI?
- How does lenvatinib fit within the evolving landscape of first-line advanced HCC therapies?
- With emerging combinations (CARES-310, CheckMate-9DW), how does lenvatinib compare in terms of efficacy/safety and clinical adoption both as monotherapy and in combination?
- As novel combinations are explored, where do you see lenvatinib fitting?
Gholam Contrasts Lenvatinib With Other Options in Child-Pugh B HCC
December 21st 2024During a Case-Based Roundtable® event, Pierre Gholam, MD, discussed how post hoc and real-world analyses build upon the limited available trial data for treating patients with unresectable hepatocellular carcinoma with Child-Pugh B status.
Read More
